Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Moffitt Cancer Center
•
HR+
•
NCI-CCC Breast Tumor Board Question
•
Breast Cancer, Non-metastatic
How do you manage adjuvant endocrine therapy for pre-menopausal women with locally advanced, weakly positive ER/PR, HER2 negative breast cancer?
Would a pCR to neoadjuvant chemotherapy change your management? (ER <5%, PR <5%)
Answer from: Medical Oncologist at Community Practice
Likely very little benefit. Reasonable to try tamoxifen if tolerated.
Sign in or Register to read more
9768
Related Questions
Is any hormonal monitoring necessary for males with breast cancer on adjuvant aromatase inhibitor and LHRH agonist (Lupron)?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
What adjuvant systemic therapy would you give a patient with pN2 nodal relapse of ER+/HER2- breast cancer now s/p ALND, after initial mastectomy, adjuvant TC, and 5 years of endocrine therapy?
For pre or perimenopausal women with early stage, hormone positive breast cancer who refuse to stop HRT (for severe perimenopausal symptoms - severe depression/anxiety/very low energy/vaginal dryness and pain with sex that's failed vaginal estrogen therapy), do you still recommend Tamoxifen or other endocrine therapy in addition to the HRT that is being taken?
With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/Her2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
What are your top takeaways in Breast Cancer from ESMO 2024?
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
Would you avoid chemotherapy in a postmenopausal woman age >65 with T3 HR+/HER2 negative with Oncotype DX < 25?